{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:18Z","timestamp":1787028618753,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["The cost of the test was covered by a special program with financial support from Sanofi Genzyme Canada."],"award-info":[{"award-number":["The cost of the test was covered by a special program with financial support from Sanofi Genzyme Canada."]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Measurement of alpha-glucosidase activity on dried blood spots has been the main method to screen for Pompe disease, but a paradigm shift has been observed in recent years with the incorporation of gene panels and exome sequencing in molecular diagnostic laboratories. An 89-gene panel has been available to Canadian physicians since 2017 and was analyzed in 2030 patients with a suspected muscle disease. Acid alpha-glucosidase activity was measured in parallel in dried blood spots from 1430 patients. Pompe disease was diagnosed in 14 patients, representing 0.69% of our cohort. In 7 other patients, low enzyme activities overlapping those of Pompe disease cases were attributable to the presence of pseudodeficiency alleles. Only two other patients had enzymatic activity in the Pompe disease range, and a single heterozygous pathogenic variant was identified. It is possible that a second variant could have been missed; we suggest that RNA analysis should be considered in such cases. With gene panel testing increasingly being performed as a first-tier analysis of patients with suspected muscle disorders, our study supports the relevance of performing reflex enzymatic activity assay in selected patients, such as those with a single GAA variant identified and those in whom the observed genotype is of uncertain clinical significance.<\/jats:p>","DOI":"10.3390\/jcm10173868","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:01:37Z","timestamp":1630321297000},"page":"3868","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular Diagnosis of Pompe Disease in the Genomic Era: Correlation with Acid Alpha-Glucosidase Activity in Dried Blood Spots"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-5464","authenticated-orcid":false,"given":"Fanny","family":"Thuriot","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada"},{"name":"Sherbrooke Genomic Medicine, Sherbrooke, QC J1H 5H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gravel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada"},{"name":"Sherbrooke Genomic Medicine, Sherbrooke, QC J1H 5H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hodson","sequence":"additional","affiliation":[{"name":"Dynacare, Laval, QC H7L 4S3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ganopolsky","sequence":"additional","affiliation":[{"name":"Dynacare, Laval, QC H7L 4S3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Rakic","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital, Vancouver, BC V6H 3N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-1859","authenticated-orcid":false,"given":"Paula J.","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gravel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada"},{"name":"Sherbrooke Genomic Medicine, Sherbrooke, QC J1H 5H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-7952","authenticated-orcid":false,"given":"S\u00e9bastien","family":"L\u00e9vesque","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada"},{"name":"Sherbrooke Genomic Medicine, Sherbrooke, QC J1H 5H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe Disease","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe Disease: Early Diagnosis and Early Treatment Make a Difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"Reuser","year":"2008","journal-title":"Lancet"},{"key":"ref_5","first-page":"82","article-title":"Clinical features of Pompe disease","volume":"32","author":"Manganelli","year":"2013","journal-title":"Acta Myol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: Identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: Design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe\u2019s Disease","volume":"362","author":"Clemens","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1542\/peds.2016-0280C","article-title":"Pompe Disease Newborn Screening Working Group; on behalf of the Pompe Disease Newborn Screening Working Group Newborn Screening for Pompe Disease","volume":"140","author":"Bodamer","year":"2017","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sawada, T., Kido, J., and Nakamura, K. (2020). Newborn Screening for Pompe Disease. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6020031"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ymgme.2006.12.006","article-title":"Rapid diagnosis of late-onset Pompe disease by fluorometric assay of \u03b1-glucosidase activities in dried blood spots","volume":"90","author":"Kallwass","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: A comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: Lessons from 28 years of experience","volume":"29","author":"Wijgerde","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2017.10.008","article-title":"Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease","volume":"122","author":"Mori","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13023-016-0390-6","article-title":"Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing","volume":"11","author":"Gravel","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1212\/NXG.0000000000000408","article-title":"Molecular diagnosis of muscular diseases in outpatient clinics","volume":"6","author":"Thuriot","year":"2020","journal-title":"Neurol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/humu.22969","article-title":"CoNVaDING: Single Exon Variation Detection in Targeted NGS Data","volume":"37","author":"Johansson","year":"2016","journal-title":"Hum. Mutat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.nmd.2017.03.010","article-title":"Screening for Pompe disease in a Portuguese high risk population","volume":"27","author":"Almeida","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ane.13133","article-title":"Screening for late-onset Pompe disease in Poland","volume":"140","author":"Lipowska","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ymgme.2018.08.009","article-title":"Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32\u201313 T > G variant","volume":"126","author":"Herbert","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-020-01353-4","article-title":"Late-onset Pompe disease (LOPD) in Belgium: Clinical characteristics and outcome measures","volume":"15","author":"Vanherpe","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13023-017-0722-1","article-title":"Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness","volume":"12","author":"Johnson","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/jhg.2016.116","article-title":"The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States","volume":"62","author":"Reddy","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"559327","DOI":"10.3389\/fneur.2020.559327","article-title":"Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent","volume":"11","author":"Chakravorty","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/acn3.649","article-title":"Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients","volume":"5","author":"Nallamilli","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1291-2","article-title":"The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease","volume":"15","author":"Bevilacqua","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamaneurol.2015.2274","article-title":"Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy","volume":"72","author":"Ghaoui","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41436-020-0840-3","article-title":"Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness","volume":"22","author":"Johnson","year":"2020","journal-title":"Genet. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nmd.2018.03.011","article-title":"Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease","volume":"28","author":"Savarese","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/NXG.0000000000000412","article-title":"Clinical utility of multigene analysis in over 25,000 patients with neuromuscular disorders","volume":"6","author":"Winder","year":"2020","journal-title":"Neurol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: A systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymgme.2013.08.005","article-title":"Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies","volume":"110","author":"Preisler","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.nmd.2015.04.008","article-title":"Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort","volume":"25","author":"Bautista","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/mtna.2016.75","article-title":"From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: A Pipeline for the Development of Antisense Oligonucleotides","volume":"5","author":"Bergsma","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry","volume":"40","author":"Reuser","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/humu.23645","article-title":"ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG\/AMP guidelines for sequence variant interpretation","volume":"39","author":"Milko","year":"2018","journal-title":"Hum. Mutat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3868\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:23Z","timestamp":1760165663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10173868"],"URL":"https:\/\/doi.org\/10.3390\/jcm10173868","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]}}}